Emerging Evolution in Piroxicam Market: Trends and Top Key Companies Profile (Pfizer, Teva, Mylan, Nostrum, DCPC, FANGMING, JINGHUA) | Global Forecast to 2025

Global Piroxicam Market overview:

The growing demand for Piroxicam has provided a major boost to the Global Piroxicam Market as more people are shifting their preferences to this growing sector. The market is expected to keep rising at a high CAGR and reach values of high millions by the end of the forecast period of 2020 up to 2024.

Get Access to Report Sample @ https://www.businessindustryreports.com/sample-request/266375

Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class used to relieve the symptoms of painful inflammatory conditions like arthritis. Piroxicam works by preventing the production of endogenous prostaglandins which are involved in the mediation of pain, stiffness, tenderness and swelling. The medicine is available as capsules, tablets and (not in all countries) as a prescription-free gel 0.5%. It is also available in a betadex formulation, which allows a more rapid absorption of piroxicam from the digestive tract. Piroxicam is one of the few NSAIDs that can be given parenteral routes. The global Piroxicam Market is primarily segmented based on Product Type, Application, End-Use Industry and Regions.

Based on Product Type, the market is divided into:

1 by Dosage Form

2 Suppositories

3 Injection

4 Capsule

5 by Route

On the basis of End Use Industry, the market is split into:

1 Tendonitis

2 Systemic Traumatic Pain

3 Musculoskeletal Pain

4 Contraception

5 Rheumatoid Arthritis/Chronic Infectious Arthritis/Osteoarthritis

Objectives of the Study

To describe and forecast the global Piroxicam Market on the basis of Product Type, industry verticals, Channel and regions.

To forecast the Piroxicam Market size of the five main regional segments, namely North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and Latin America.

To strategically analyzesubsegments with respect to individual growth trends, future prospects, and contribution to the total market.

To provide detailed information regarding the major factors influencing the growth of the Piroxicam Market (drivers, restraints, opportunities, and challenges).

To analyze the opportunities in the market for stakeholders and to provide details of competitive landscape for major players.

To strategically profile key players and comprehensively analyze their core competencies and positioning.

To track and analyze competitive developments such as mergers and acquisitions, new product developments, and partnerships, agreements & collaborations in the Piroxicam Market.

�

Some of the Piroxicam Market manufacturers involved in the market are Pfizer, Teva, Mylan, Nostrum, DCPC, FANGMING, JINGHUA, JUMPCAN, Technilab Pharma, Apotex Corporation, Keltman Pharmaceuticals, Genpharm, Bayer, PLX Pharma, Chiesi, SK Chemicals, Bioglan Laboratories, APR, CJ HealthCare, SkyePharma, Changzhou Siyao Pharmaceutical, Shanxi Yunpeng Pharmaceutical, Acquisitions and effective mergers are some of the strategies adopted by the Piroxicam Market manufacturers. New product launches and continuous technological innovations are the Piroxicam Market strategies adopted by the major players.

Latest Industry Updates:

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics. Tanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF) inhibitors.

�

More than 27 million Americans are living with OA, 11 million of whom have moderate-to-severe OA. Currently available treatment options for moderate-to-severe OA do not meet the needs of all patients, and many cycle through multiple therapies to find relief from their pain. The Prescription Drug User Fee Act (PDUFA) goal date for the FDA to make a decision on the tanezumab application is in December 2020. In its acceptance letter, the FDA stated that it is currently planning to hold an Advisory Committee meeting to discuss this application.

"The FDA acceptance of the tanezumab application represents a significant milestone, and the breadth of our regulatory submission reflects the extensive clinical data we have gathered for tanezumab over the course of its development," said Ken Verburg, tanezumab development team leader, Pfizer Global Product Development. "There is an urgent need for innovation in the treatment of osteoarthritis, as there have been no new classes of medicines available for this debilitating condition in more than a decade. If approved, tanezumab would be a first-in-class treatment for patients suffering from chronic pain due to moderate-to-severe osteoarthritis who have experienced inadequate pain relief with other analg.

Buy Piroxicam Market analysis & forecast 2020-2024 Report along with complete TOC@ https://www.businessindustryreports.com/buy-now/266375/single

Asia Pacific was a prominent market for Piroxicams in 2016. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income. Increased spending on home interiors is fuelling the Piroxicam market in Asia Pacific.

There are several manufacturers of Piroxicams in Europe and North America. In North America, the demand for Piroxicams is primarily driven by the residential sector. Improved standards of living and rising usage of Piroxicams for flooring purpose are anticipated to drive the market in North America.

Get Best Discount On This Report @ https://www.businessindustryreports.com/check-discount/266375

Table of Contents:

Global Piroxicam Market Report 2020

1 Piroxicam Definition

2 Global Piroxicam Market Major Player Share and Market Overview

3 Major Player Piroxicam Business Introduction

4 Global Piroxicam Market Segmentation (Region Level)

5 Global Piroxicam Market Segmentation (Product Type Level)

6 Global Piroxicam Market Segmentation (Industry Level)

7 Global Piroxicam Market Segmentation (Channel Level)

8 Piroxicam Market Forecast 2020-2024

................... Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined - we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune - India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.